Memorial Sloan Kettering Cancer Center

Ajax Therapeutics, Inc. is going after an old target in myelofibrosis and other myeloproliferative neoplasms (MPNs) in a new way with its type II JAK2 inhibitor, AJ1-11095, which it will take into th

Venture capital fundraising by biopharmaceutical companies has been a mixed bag so far in 2023, with a slow start to the year but a relative surge in big financings in March and April. There were only

March has been a big month for venture capital mega-rounds of $100m or more and Flare Therapeutics Inc. continued the trend, announcing 22 March that it completed a $123m series B round to fund disc

Erasca Five-Year Collaboration With MD Anderson Focused On MAPKlamp Combo Precision oncology-focused Erasca, Inc. inked a research and development collaboration on 23 August with the University of